Patients with multiple myeloma (MM) have improved treatment options, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Despite their efficacy, increased rates of cardiovascular (CV) complications occur in patients exposed to some of these therapies. While previous research has focused on identifying the toxicities inherent to each specific agent, the CV side effects may be potentiated by the combination of PIs and IMiDs plus dexamethasone. We present a patient with MM with recurrent cardiotoxicity only when exposed to combination PI and IMiD-based therapy. We also review the literature in this context, and propose a potential algorithm for cardiotoxicity prevention in this population.
Treatment options for multiple myeloma (MM) have increased significantly over the last decade with the advent of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). These therapies have markedly improved overall survival in this otherwise incurable haematological malignancy (Richardson et al, 2007) ; however, there has been increased recognition of cardiovascular (CV) complications in MM patients, including hypertension, left ventricular (LV) dysfunction, heart failure (HF) and both arterial (ATE) and venous (VTE) thromboembolic events (Li et al, 2017) . Less clear are the CV risks of these therapies when used in combination. We present a 42-year-old woman without significant CV history who experienced recurrent cardiotoxicities only when exposed to both PIs and IMiDs in combination. This case highlights the synergistic effects of these treatments while demonstrating the compelling need for enhanced understanding of the mechanism of toxicity in order to develop improved CV risk reduction strategies.
Case report
The patient, a 42-year-old woman with a 3-year history of IgA kappa, Durie Salmon stage 3A MM, was first diagnosed in 2013. Due to pre-existing peripheral neuropathy (PN), she was treated with front-line carfilzomib, lenalidomide and dexamethasone (KRd). A pre-treatment echocardiogram demonstrated normal LV function. She had no previous CV disease or risk factors. Aspirin prophylaxis was administered ethasone 20 mg, she developed severe chest pain and sustained ventricular tachycardia. Troponin T peaked at 23 ng/ ml (normal ≤0Á03 ng/ml). Coronary angiography was negative for obstructive coronary disease. Cardiac magnetic resonance imaging (MRI) demonstrated late gadolinium enhancement (LGE), suggesting extensive myocardial fibrosis primarily affecting the basal and mid-anterior and inferolateral LV, which persisted even after cessation of therapy and symptom resolution (Fig 1) . For the next 12 months, she was maintained on intermittent dexamethasone. Due to disease progression, bortezomib was subsequently added but then changed to ixazomib followed by the addition of lenalidomide. Approximately 3 weeks after the initiation of dose-attenuated lenalidomide, she developed sharp chest pain and palpitations similar in quality to her event 2 years earlier, prompting emergency evaluation. Her troponin T peaked at 1Á040 ng/ml. A coronary computed tomography scan was normal (calcium score 0). A repeat MRI scan demonstrated interval development of LGE affecting primarily the basal inferior and inferoseptal walls (Fig 1) . These findings were most consistent with a chronic inflammatory/ fibrotic process, such as myocarditis. She was treated with a dexamethasone taper with complete resolution of her symptoms. Due to recurrent CV events, she was first observed with bisphosphonate alone and has since been re-started on bortezomib combined with low dose dexamethasone without significant complications.
Discussion
As biologically derived backbone agents, PIs and IMiDs have become part of the standard of care in modern MM treatment. These agents are clinically synergistic although via different mechanisms. There are currently three US Food and Drug Administration (FDA) approved PIs -bortezomib, carfilzomib and ixazomib, and three FDA approved IMiDsthalidomide, lenalidomide and pomalidomide. Despite the anti-cancer efficacy of these agents, CV toxicity is increasingly recognized as an important side effect of some of these agents (Table I) . Among the PIs, a cardiotoxicity signal has only been established with carfilzomib. Safety analyses from four phase II single-agent carfilzomib trials in relapsed and/or refractory MM (RRMM) demonstrated cardiotoxicity in 22Á1% of patients, which included arrhythmias (13Á3%), HF (7Á2%), hypertension (14Á3%) and, rarely, CV death (1Á5%) . In the ENDEAVOR (Randomized, open label, phase 3 study of carfilzomib plus dexamethasone vs bortezomib plus dexamethasone in patients with relapsed multiple myeloma) trial, hypertension was reported in 25% of patients receiving combination carfilzomib and dexamethasone with grade 3 or higher CV events occurring in 9% (compared to 3% in the bortezomib treated arm) . Although the specific cardiotoxicities are unclear, these probably do not represent a class-related effect as recent data suggest low cardiotoxicity associated with bortezomib .
Both ATEs and VTEs are commonly observed cardiotoxicities associated with IMiDs. In a randomized trial of lenalidomide with either high-dose or low-dose dexamethasone, VTE incidence was 26% and 12% respectively (Li et al, 2017) . Long term data from two phase III trials comparing combination lenalidomide and dexamethasone to dexamethasone alone in RRMM patients, demonstrated an increased incidence of myocardial infarction (MI) and cerebrovascular events (1Á98% and 3Á4% vs. 0Á57% and 1Á7% respectively) (Dimopoulos et al, 2009) . As a result, lenalidomide has a "black box" FDA warning for MI and stroke in this population.
In clinical practice, PI and IMiDs are frequently co-administered along with dexamethasone and, as such, cardiotoxicity may be potentiated by interactions of these drugs. In a study of 84 patients with RRMM treated with KRd, all grade and high-grade cardiac adverse events were reported at 19% and 7%, respectively (Wang et al, 2013) . In the phase III ASPIRE (Carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma) trial comparing the efficacy of KRd to lenalidomide and dexamethasone alone, the carfilzomib arm demonstrated higher rates of CV complications including HF (6Á4% vs. 4Á1%), ischaemic heart disease (5Á9% vs. 4Á6%), hypertension (14Á3% vs. 6Á9%) and VTE (10Á2% vs. 6Á2%) (Stewart et al, 2015) . These data suggest significantly increased CV toxicity with combination PI and IMiD therapy which may be due to vascular toxicity rather than myocardial dysfunction alone.
The mechanism of PI-and IMiD-associated cardiotoxicity has yet to be fully elucidated. PIs inhibit proteasome activity, leading to the accumulation of abnormal proteins which in turn activates apoptotic pathways in MM cells (Mitsiades, 2015) . In contrast, IMiDs bind cereblon, a component of the E3 ubiquitin ligase which promotes proteasome-mediated degradation of the transcription factors, IKZF1 and IKZF (Li et al, 2017) . It is unclear if the protein degradation properties of these drugs contribute to cardiotoxicity, although clinical features of the toxicity suggest endothelial cell injury and dysfunction. It is possible that CV events may be augmented when these two classes of medications are co-administered and further enhanced by the additional endothelial stress conferred by steroids (Li et al, 2017) .
We advocate for proactive CV risk factor management in all patients receiving PI, IMiD and steroid therapy for MM. All MM patients should be carefully educated about the potential therapy-induced cardiotoxicities, and we recommend optimizing CV and metabolic risk factors during MM treatment. Thromboembolism prophylaxis and blood pressure control are particularly relevant to MM patients. Given the increased risk of thromboembolism, all patients should be offered aspirin, with certain higher risk subpopulations treated with full anticoagulation (Palumbo et al, 2008; Li et al, 2017) . Additionally, hypertension, an established CV risk factor, can be accelerated by MM treatments, particularly carfilzomib and steroids (Li et al, 2017) . We advocate for a blood pressure goal of <140/90 mmHg, and suggest angiotensin-converting enzyme inhibitors as first-line therapies given their mortality benefits. Of note, screening echocardiography has not been shown to significantly reduce CV risk .
Conclusion
Outcomes for MM have improved dramatically primarily due to the introduction of PI and IMiD-based therapies. CV toxicities with these combinations have been observed with increasing frequency. Further research is necessary to fully define the specific toxicities and to elucidate mechanisms of cardiotoxicity to prevent and manage these complications. Collaboration between cardiologists and haematologists/oncologists are needed to optimize CV health in MM patients, while ensuring delivery of the best available MM therapies and ultimately improving patient outcomes.
